Natera
Natera Enrolls First Patients in HEROES Metastatic HER2+ Breast Cancer Trial
Natera's Signatera test and diagnostic imaging will be used to monitor patients for progression-free survival over the course of one year.
Natera MRD Test Receives MolDx Coverage for Lung Cancer Surveillance
The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial
Investigators are using the Signatera ctDNA test to guide treatment decisions for high-risk colon cancer patients based on their tumor genetics.